You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,439,905

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,439,905 protect, and when does it expire?

Patent 9,439,905 protects UZEDY and is included in one NDA.

This patent has twenty-eight patent family members in eight countries.

Summary for Patent: 9,439,905

Patent landscape, scope, and claims:

Title:	Risperidone-containing implants and methods of use thereof
Abstract:	The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Inventor(s):	Siegel Steven, Winey Karen
Assignee:	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Application Number:	US14286168
Patent Claim Types: see list of patent claims
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,439,905

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-001	Apr 28, 2023		RX	Yes	No	9,439,905	⤷ Subscribe	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-002	Apr 28, 2023		RX	Yes	No	9,439,905	⤷ Subscribe	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-003	Apr 28, 2023		RX	Yes	No	9,439,905	⤷ Subscribe	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-004	Apr 28, 2023		RX	Yes	No	9,439,905	⤷ Subscribe	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-005	Apr 28, 2023		RX	Yes	No	9,439,905	⤷ Subscribe	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,439,905

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005206143	⤷ Subscribe
Australia	2006269927	⤷ Subscribe
Canada	2553254	⤷ Subscribe
Canada	2614601	⤷ Subscribe
China	101287423	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.